A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas - Gore, L; Rothenberg, M L; O’Bryant, C L (Clin Cancer Res, 2008)
et al.